| Bioactivity | ZYJ-34v 是一种具有口服活性的组蛋白去乙酰化酶 (histone deacetylase) 抑制剂。ZYJ-34v 具有抗肿瘤活性。 |
| Invitro | ZYJ-34v 对 HDACs 具有抑制作用，对 MDA-MB-231, HCT116, PC-3, HepG2, MCF-7 细胞的 IC50 值分别为 1.41, 0.63, 2.62, 4.23 和 4.76 μM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> ZYJ-34v 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | ZYJ-34v (90 mg/kg, 口服, 连续 22 天) 在 MDA-MB-231 异种移植肿瘤模型中具有抗肿瘤活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1450662-32-4 |
| Formula | C27H35N3O6 |
| Molar Mass | 497.58 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang Y, et al. Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity. Chem Biol Drug Des. 2013 Aug;82(2):125-30. |